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Introduction: The chemokine CXCL10 is produced during infection and inflammation to activate the chemokine
receptor CXCR3, an important regulator of lymphocyte trafficking and activation. The goal of this study was to
assess the contributions of CXCL10 to the pathogenesis of experimental septic shock in mice.
Methods: Septic shock was induced by cecal ligation and puncture (CLP) in mice resuscitated with lactated Ringer’s
solution and, in some cases, the broad spectrum antibiotic Primaxin. Studies were performed in CXCL10 knockout mice
and mice treated with anti-CXCL10 immunoglobulin G (IgG). Endpoints included leukocyte trafficking and activation,
core body temperature, plasma cytokine concentrations, bacterial clearance and survival.
Results: CXCL10 was present at high concentrations in plasma and peritoneal cavity during CLP-induced septic shock.
Survival was significantly improved in CXCL10 knockout (CXCL10KO) mice and mice treated with anti-CXCL10 IgG
compared to controls. CXCL10KO mice and mice treated with anti-CXCL10 IgG showed attenuated hypothermia,
lower concentrations of interleukin-6 (IL-6) and macrophage inhibitory protein-2 (MIP-2) in plasma and lessened
natural killer (NK) cell activation compared to control mice. Compared to control mice, bacterial burden in blood
and lungs was lower in CXCL10-deficient mice but not in mice treated with anti-CXCL10 IgG. Treatment of mice
with anti-CXCL10 IgG plus fluids and Primaxin at 2 or 6 hours after CLP significantly improved survival compared
to mice treated with non-specific IgG under the same conditions.
Conclusions: CXCL10 plays a role in the pathogenesis of CLP-induced septic shock and could serve as a therapeutic
target during the acute phase of septic shock.Introduction
The CXC chemokine CXCL10 (also known as interferon-
inducible protein 10 (IP-10)) is produced during periods
of infection and inflammation in response to type I
and type II interferons (IFN) such as IFNα/β and IFNγ,
respectively [1-4]. CXCL10 activates the G-protein coupled
chemokine receptor CXCR3, an important regulator of
natural killer (NK), natural killer T (NKT) and T helper
(Th)1 lymphocyte trafficking, in response to viral infections,
autoimmune diseases, allotransplantation and cancer
[5-10]. Recently, a role for CXCR3 activation in the
pathogenesis of severe sepsis has been proposed [11].
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unless otherwise stated.less systemic cytokine production, attenuated physiologic
dysfunction and improved survival during severe sepsis
caused by cecal ligation and puncture (CLP) [11]. Large
numbers of CXCR3+ NK cells migrate from the spleen
and blood into the peritoneal cavity during CLP-induced
sepsis, a phenomenon that is ablated in CXCR3-deficient
mice as well as in mice treated with neutralizing anti-
bodies against CXCR3 [11,12]. Thus, the trafficking of NK
cells to the site of infection after CLP parallels the devel-
opment of systemic inflammation and mortality. Both
phenomena are ablated by CXCR3 deficiency or blockade,
which raises the contention that the improved outcomes
observed in septic mice with CXCR3 deficiency or block-
ade are due to attenuated trafficking and activation of
innate lymphocyte populations. However, further research
is needed to determine the mechanisms by which CXCR3
activation facilitates the pathogenesis of septic shock.
High concentrations of CXCL10 are present in peritoneal
lavage fluid and plasma during CLP-induced septic shockLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trafficking of NK cells into the inflamed and infected peri-
toneal cavity. Furthermore, high CXCL10 concentra-
tions correlate with the development of physiologic
dysfunction and death in the CLP model of sepsis [11].
In clinical studies, plasma CXCL10 concentrations are
markedly elevated in septic patients and plasma CXCL10
concentrations correlate with the severity of sepsis in
humans [4,13,14]. Punyadeera et al. [14] reported that
elevated plasma CXCL10 concentrations are predictive
of the transition from sepsis to septic shock in critically
ill adults. In other studies, elevated plasma CXCL10
concentrations have been shown to be a reliable indicator
of sepsis in neonates and infants [15,16]. However, the
functional importance of CXCL10 in the pathogenesis of
severe sepsis has not been ascertained.
In the present study, the effect of CXCL10 deficiency
or blockade on the pathogenesis of CLP-induced septic
shock was investigated. Survival, core body temperature,
bacterial clearance and systemic cytokine production as
well as lymphocyte trafficking and activation were eval-
uated in CXCL10-deficient mice and in mice treated
with neutralizing antibody against CXCL10. CXCL10
blockade was initiated prior to or after the onset of
sepsis. In the latter studies, the goal was to determine
whether CXCL10 blockade might serve as a therapeutic
target during experimental septic shock.
Methods
Mice
Female and male, 10- to 12-week-old C57BL/6 J wild-type
mice and homozygous CXCL10-null mice (B6.129S4-
Cxcl10tm1Adl/J, CXCL10KO) were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA). CXCL10KO
mice were genotyped at our facility to assure authenticity.
All studies were approved by the Institutional Animal
Care and Use Committees at the University of Texas
Medical Branch and Vanderbilt University Medical Center
and complied with the National Institutes of Health Guide
for the Care and Use of Experimental Animals, which
conforms to internationally recognized guidelines for the
ethical treatment of animals.
Cecal ligation and puncture (CLP)
CLP was performed as previously described [11]. Briefly,
mice were anesthetized with 2 to 3% isoflurane in oxy-
gen. After shaving and aseptic preparation of the surgical
site, a 1- to 2-cm midline incision was made through the
abdominal wall; the cecum was identified and ligated
with a 3-0 silk suture at 0.5 to 1 cm from the tip,
depending on the desired severity of the model. A
double puncture of the cecal wall was performed with a
20-gauge needle. The incision was closed with 3-0 Pro-
lene suture. Mice were resuscitated with intraperitonealinjection of 1 ml of lactated Ringer’s (LR) solution, with or
without primaxin (25 mg/kg, Merck & Co, Whitehouse
Station, NJ, USA), immediately after CLP. Primaxin is a
formulation of imipenem (a potent, broad-spectrum thie-
namycin antibiotic) and cilastatin sodium (the inhibitor of
the renal dipeptidase, dehydropeptidase I). Mice received
buprenorphene (0.1 mg/kg) subcutaneously at 30 minutes
prior to CLP and twice daily thereafter for analgesia.
Experimental protocols
Anti-CXCL10 pretreatment experiments
Mice received intraperitoneal injection with polyclonal
anti-CXCL10 IgG or nonspecific IgG (100 μg, R&D Sys-
tems, Minneapolis, MN, USA) at 1 hour before CLP. Mice
were resuscitated with lactated Ringer’s (LR) solution con-
taining primaxin immediately after CLP. Subsets of mice
were monitored for survival. In additional mice, rectal
temperature was measured and samples were harvested
for measurement of tissue and blood bacterial burden and
cytokine concentrations.
Anti-CXCL10 post-treatment experiments
Mice underwent CLP and received intravenous treatment
with polyclonal anti-CXCL10 IgG or non-specific IgG
(100 μg in 0.2 ml LR) at 2 or 6 hours after CLP. At the
time of IgG treatment, mice also received intraperitoneal
injection with LR plus primaxin. Antibodies were given
intravenously in the post-treatment experiments to speed
systemic dissemination. Mice were monitored for survival
for 7 days after CLP.
Recombinant CXCL10 treatment experiments
Mice underwent CLP and were treated with intravenous
(IV) recombinant mouse CXCL10 (R&D Systems) at 1 ug/
mouse, or vehicle at 8 hours after CLP. Mice were moni-
tored for survival and rectal temperature was measured at
the indicated time points. Mice received intraperitoneal
resuscitation with LR immediately after CLP.
Flow cytometry
Splenic and intraperitoneal leukocytes were harvested as
previously described [11,17]. Measurements of NK cell
numbers were made at 6 hours after CLP in mice that
did not receive antibiotic treatment. Our previous studies
show significant NK cell migration into the peritoneal
cavity at 6 to 8 hours after CLP [11]. Briefly, spleens
were harvested and placed in 35-mm dishes containing
RPMI-1640 media with 10% fetal bovine serum, and
mashed with the plunger from a 1-ml syringe. The sple-
nocyte suspensions were passed through a 70-μm nylon
mesh and erythrocytes were lysed (Erythrocyte Lysis Kit;
R&D Systems). Isolated splenocytes were resuspended
(1 × 107 cells/ml) in PBS. Intraperitoneal leukocytes were
harvested by lavage with 3 ml of PBS. After washing and
Figure 1 CXC chemokine 10 (CXCL10) concentrations in plasma
and peritoneal lavage during cecal ligation and puncture (CLP)-
induced sepsis. Plasma and peritoneal lavage were harvested at the
indicated time points after CLP. CXCL10 concentrations were measured
by ELISA: n = 10 mice per group: *P <0.05 compared to 0-hour control,
+P <0.05 compared to plasma.
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Cell viability was greater than 95% in all cases as deter-
mined by trypan blue exclusion.
Isolated leukocytes (1 × 106/tube) were placed in poly-
styrene tubes and incubated with anti-mouse CD16/32
(eBioscience, San Diego, CA, USA) to block non-specific
Fc receptor-mediated antibody binding. Fluorochrome-
conjugated antibodies or isotype controls (0.5 to 1 g/tube)
were added, incubated (4°C) for 30 minutes, and washed
with 2 ml of cold PBS. Cells were fixed with 250 μl of
1% paraformaldehyde. Antibodies used in the analyses
included anti-CD3, anti-NK1.1, anti-CD11b and anti-CD27
(eBioScience) as well as appropriate isotype control anti-
bodies. Samples were analyzed with an Accuri C6 flow
cytometer (BD Biosciences). Data were analyzed using
Accuri C6 software.
Cytokine measurements
Heparinized blood was obtained by carotid laceration and
plasma was harvested following centrifugation (2000 × g
for 15 minutes). The peritoneal cavity was lavaged with
3 ml of sterile PBS. Urea was used as a standard for
dilution of peritoneal lavage samples because urea readily
diffuses freely throughout the tissue and fluid compart-
ments. When the urea concentrations in plasma and a
peritoneal lavage sample are known, the dilution of the
initial volume of peritoneal fluid obtained can be calcu-
lated as previously described [18,19]. The urea content of
peritoneal lavage and plasma samples were determined
using iStat Chem8 cartridges (Abbott Point of Care,
Princeton, NJ, USA). CXCL10, IL-6 and macrophage in-
hibitory protein-2 (MIP-2) concentrations were measured
using ELISA according to the manufacturer’s protocols
(eBioscience). Cytokine concentrations were determined
by measuring optical density at 450 nm using a microtiter
plate reader (Dynatech Laboratories, Chantilly, VA, USA).
Previous studies from our laboratory, and others, show
that the magnitude of systemic IL-6 and MIP-2 produc-
tion during CLP-induced sepsis parallels the severity of
physiologic dysfunction and mortality [11,20]. Thus, those
cytokines were used as markers of systemic inflammation.
Measurement of temperature and bacterial counts
Body temperature was measured by insertion of a lubri-
cated rectal temperature probe prior to and at various
times after CLP. Previous studies show that the magnitude
of hypothermia correlates with mortality in the CLP
model [11]. Thus, rectal temperature was used as a
marker of physiological dysfunction in our model. Arterial
blood gas analysis was performed on heparinized blood
using CG4+ iStat Cartridges (Abbott Diagnostics). Bacter-
ial counts were performed on blood, peritoneal lavage
fluid and lung homogenates. Samples of blood and peri-
toneal lavage fluid were obtained as described above. Lungtissue was harvested under aseptic conditions, weighed
and homogenized in sterile PBS to achieve a final concen-
tration of 11 mg of tissue per ml of saline. Samples were
serially diluted in sterile saline and plated on tryptic soy
agar. Plates were incubated (37°C) for 24 to 48 hours and
colony counts were performed by direct visualization.
Statistics
All data were analyzed using GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). Data from
multiple group experiments were analyzed using one-
way analysis of variance (ANOVA) followed post hoc by
the Tukey multi-comparison test. Comparison of data from
experiments using two groups of subjects was achieved
using the unpaired t-test. For measurements of bacterial
colony-forming units (CFU), groups were compared using
the nonparametric Kruskal-Wallis test, followed post hoc
by Dunn’s test. Survival data were analyzed using the log
rank test. A value of P <0.05 was considered statistically
significant for all experiments. All values are presented as
the mean ± standard error of the mean (SEM), except for
bacterial counts, for which median values are designated.
Results
CXCL10 production during CLP-induced sepsis
Concentrations of CXCL10 increased in plasma and the
peritoneal cavity within 4 hours after CLP and remained
elevated at 8 and 16 hours with the highest concentrations
being measured at 8 hours after CLP (Figure 1). CXCL10
concentrations in peritoneal lavage were significantly higher
than in plasma at 4, 8 and 16 hours after CLP. CXCL10
was not detectable in plasma or peritoneal lavage fluid in
CXCL10 knockout (CXCL10KO) mice (data not shown).
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and plasma cytokine concentrations during CLP-induced
sepsis
Survival was measured in control- and CXCL10-deficient
mice (Figure 2). In the absence of antibiotic treatment,
CXCL10 knock-out (CXCL10KO) mice showed signifi-
cantly higher survival rates compared to wild-type mice
(60% versus 10%). Likewise, CXCL10KO mice resuscitated
with fluids and antibiotics at the time of CLP showed
significantly higher survival rates compared to wild-type
mice (60% versus 13%). Although survival was prolonged
in mice receiving antibiotics, overall mortality rates were
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Figure 2 Survival of wild-type and CXC chemokine 10 (CXCL10)-defici
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that received primaxin as part of the resuscitation
protocol (Figure 3). Those time points were chosen due to
the effect of antibiotic treatment on time to initial mor-
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Figure 3 (See legend on next page.)
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Figure 3 Effect of CXC chemokine 10 (CXCL10) deficiency on core body temperature and plasma cytokines during cecal ligation and
puncture (CLP)-induced sepsis. Rectal temperature and plasma IL-6 and Macrophage inhibitory protein-2 (MIP-2) concentrations were measured
in mice treated with or without primaxin after CLP: n = 10 mice per group; *P <0.05 compared to control, +P <0.05 compared to wild-type mice.
WT, wild-type. Measurements were made at the onset of mortality in our model: at 24 hours post-CLP in mice that received primaxin and 12 hours
post-CLP in mice that did not receive antibiotics.
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were made at the time on mortality onset in the respective
groups. In mice that did not receive primaxin treatment,
rectal temperature was significantly decreased in wild-
type, but not CXCL10KO, mice compared to non-septic
controls. Rectal temperature was significantly higher in
CXCL10KO mice compared to wild-type mice (Figure 3).
Wild-type and CXCL10KO mice treated with Primaxin
exhibited significantly decreased rectal temperature at
24 hours after CLP compared to non-septic controls. Rec-
tal temperature was significantly higher in CXCL10KO
mice compared to wild-type mice (Figure 3).
Plasma IL-6 and MIP-2 concentrations were also mea-
sured at 12 or 24 hours after CLP in mice treated without
or with primaxin, respectively (Figure 3). In mice that
did not receive treatment with primaxin, plasma IL-6
and MIP-2 concentrations were significantly lower in
CXCL10KO mice compared to wild-type mice. In mice
that received primaxin treatment, plasma MIP-2 but
not IL-6 concentrations were lower in CXCL10KO
mice compared to wild-type mice.
Effect of CXCL10 deficiency on bacterial clearance during
CLP-induced sepsis
Bacterial counts were measured in control and CXCL10-
deficient mice that were treated with or without Primaxin
(Figure 4). Treatment with Primaxin significantly decreased
bacterial counts in the peritoneal cavity, blood and lungs
by greater than two orders of magnitude compared to
the same tissues from mice that did not receive pri-
maxin treatment (Figure 4). Significant differences in
intraperitoneal bacterial counts were not observed when
comparing CXCL10KO and wild-type mice, regardless
of whether primaxin was given (Figure 4). Bacterial
counts in blood and lung were significantly lower in
CXCL10KO mice than in wild-type mice when primaxin
was not given. However, in primaxin-treated mice, no
differences in bacterial burden were observed in blood
and lungs when comparing wild-type and CXCL10KO
mice (Figure 4).
Effect of CXCL10 blockade on lymphocyte trafficking
and activation
Studies were undertaken to assess lymphocyte trafficking
in wild-type and CXCL10KO mice after CLP. All studies
were performed in the absence of antibiotic treatment.
Natural killer (NK) cells can be subdivided into immature(I, CD27+CD11b−), pro-inflammatory (II, CD27+CD11b+)
and cytotoxic (III, CD27−CD11b+) subsets based on CD27
and CD11b expression (Figure 5) [21]. The upper panels
of Figure 5 shows the gating strategy used to identify
NK cell subsets. Total NK cells were identified as
NK1.1+CD3− lymphocytes (Figure 5). NK cell subsets
were identified as pro-inflammatory or cytotoxic based
on CD27 and CD11b expression as described above. A
significant decline in total, pro-inflammatory and cyto-
toxic NK cells was observed in the spleen by 6 hours after
CLP and corresponded with an increase in intraperitoneal
numbers of the same NK cell subsets over the same time
period (Figure 5). The numbers of immature NK cells in
spleen and peritoneal lavage did not change during the
first 6 hours after CLP (data not shown). No significant
difference in splenic or intraperitoneal NK cell numbers
was noted when comparing wild-type and CXCL10KO
mice (Figure 5). The numbers of T (NK1.1−CD3+) or
NKT (NK1.1+CD3+) cells in spleen and peritoneal lavage
did not change at 6 hours after CLP in either group (data
not shown).
Further studies were undertaken to assess early activation
of intraperitoneal lymphocytes using CD69 as a biomarker
(Figure 6). Intraperitoneal NK, T and NKT lymphocytes
from wild-type mice showed evidence of activation after
CLP as indicated by significantly increased percentages of
CD69-positive cells and increased CD69 mean fluorescence
intensity (MFI) (Figure 6). At 6 hours post-CLP, the per-
centage of CD69+ NK cells and the CD69 MFI on NK cells
were significantly lower in CXCL10KO mice compared to
wild-type mice. For T and NKT cells, the percentages of
CD69+ cells and the CD69 MFI were not significantly
different when comparing lymphocytes from wild-type
and CXCL10KO mice (Figure 6).Effect of CXCL10 blockade on survival, core body
temperature, plasma cytokine concentrations and
bacterial burden during CLP-induced sepsis
Studies were undertaken to determine whether blockade
of CXCL10 alters survival during CLP-induced sepsis
(Figure 7). Wild-type mice were treated with anti-CXCL10
IgG or non-specific IgG at 1 hour prior to CLP. Mice were
resuscitated with LR and primaxin at the time of CLP.
Survival was significantly improved in mice treated with
anti-CXCL10 IgG compared to mice treated with non-
specific IgG (40% versus 7%, Figure 7).
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Figure 4 Effect of CXC chemokine 10 (CXCL10) deficiency on bacterial burden during during cecal ligation and puncture (CLP)-induced
sepsis. Bacterial colony forming units (CFU) were measured in mice treated with or without primaxin after CLP; n = 10 to 20 mice per group;
*P <0.05 compared to wild-type, +P <0.05 compared to mice that did not receive primaxin treatment. Measurements were made at the onset of
mortality in our model: at 24 hours post-CLP in mice that received primaxin and 12 hours post-CLP in mice that did not receive antibiotics.
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and MIP-2 concentrations were measured in wild-type
mice treated with anti-CXCL10 IgG or non-specific IgG
(Figure 8). Mice were resuscitated with LR plus primaxin.
CLP induced a significant decrease in temperature in
wild-type mice treated with non-specific IgG compared
to non-septic controls. Rectal temperature was not sig-
nificantly decreased in mice treated with anti-CXCL10
IgG compared to non-septic controls and was signifi-
cantly higher than in mice treated with non-specific
IgG (Figure 8). Examination of plasma cytokines showed
that IL-6 and MIP-2 concentrations were significantly
lower in the anti-CXCL10 IgG group compared to the
non-specific IgG group (Figure 8).
Bacterial counts were measured in mice that were treated
with or without primaxin (Figure 9). Bacterial counts in
peritoneal lavage fluid, blood and lungs were not signifi-
cantly different between mice treated with non-specific
IgG or anti-CXCL10 IgG, regardless of whether mice were
treated with primaxin (Figure 9). Bacterial counts at all
measured sites were significantly lower in mice treated
with primaxin compared to those that did not receive
primaxin treatment (Figure 9).
Effect of anti-CXCL10 IgG treatment on survival when
administered after the onset of sepsis
Studies were undertaken to assess whether initiation of
CXCL10 blockade after the onset of sepsis would improve
survival. Initial studies were undertaken to characterize
the progression of sepsis in our model and determine
whether evidence of sepsis was present at the time of anti-
CXCL10 IgG treatment (Figure 10). Rectal temperature
was measured at the indicated time points and showed
a significant decline at 4 hours after CLP and a further
decline at 6 hours after CLP compared to non-septic
(0 hours) mice (Figure 10). Assessment of acid-base
balance at 6 hours after CLP showed metabolic acidosis
compared to sham mice, characterized by a significant
decrease in blood pH and bicarbonate concentrations
(Figure 10). PaCO2 was also significantly lower in septic
mice compared to sham controls, reflecting respira-
tory compensation for the emerging metabolic acidosis
(Figure 10). Plasma concentrations of IL-6 and MIP-2
were significantly increased at 6 hours after CLP and
mice were also bacteremic at that time point as indicated
by positive blood cultures in all mice (Figure 10).
Mice were treated with anti-CXCL10 IgG or non-specific
IgG in combination with fluids and primaxin at 2 or6 hours after the CLP procedure (Figure 11). Survival
was significantly improved in wild-type mice treated
with anti-CXCL10 IgG at 2 hours (65% versus 25%) and
6 hours after CLP (40% versus 15%) compared to mice
treated with non-specific IgG (Figure 11).
Discussion
The present study shows that CXCL10 deficiency or
blockade confers protection from CLP-induced septic
shock in mice, regardless of whether antibiotics are
given. Sepsis-induced hypothermia and systemic cytokine
production were attenuated and survival rates were higher
in CXCL10-deficient mice and in mice treated with a neu-
tralizing antibody against CXCL10, compared to control
mice. Collectively, those observations support the conten-
tion that CXCL10 plays a functional role in facilitating
inflammation and physiology during CLP-induced acute
septic shock. In addition, CXCL10 blockade could serve as
a therapeutic target during acute septic shock, as treatment
with anti-CXCL10 IgG and antibiotics was effective in
improving survival when administered at 2 or 6 hours after
the onset of sepsis. The improvement in survival observed
when mice were treated with anti-CXCL10 IgG at 6 hours
after CLP was particularly compelling because mice showed
clinical signs of sepsis such as hypothermia, metabolic acid-
osis, systemic inflammation and bacteremia at the time of
treatment.
CXCL10 has been shown to serve as a useful biomarker
in human sepsis. Several studies have reported increased
concentrations of CXCL10 in the plasma of septic human
adults, infants and neonates [4,13,15,16]. Punyadeera and
colleagues showed that high plasma CXCL10 concentra-
tions are associated with the transition from sepsis to
septic shock in critically ill adult patients [14]. Elevated
plasma CXCL10 concentrations have also been shown to
be a reliable indicator of sepsis in neonates and infants
[15,16]. However, the functional importance of CXCL10
in facilitating the pathogenesis of severe bacterial sepsis
had not been directly examined. Yet, prior studies have
shown that CXCL10 contributes to acute organ injury
and physiologic dysfunction in other acute inflammatory
syndromes. Ichikawa and colleagues showed that mice
lacking CXCL10 are resistant to acute lung injury caused
by acid aspiration or influenza virus infection [22]. CXCL10
neutralization has been effective in attenuating NK and
CD8 T cell-mediated hepatocellular injury during fulminant
Dengue virus infection [23]. A role for CXCL10 in the
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Figure 5 (See legend on next page.)
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Figure 5 Natural killer cell trafficking during cecal ligation and puncture (CLP)-induced sepsis in wild-type and CXC chemokine 10
(CXCL10)-deficient mice. Splenocytes and intraperitoneal leukocytes were harvested prior to or 6 hours after CLP. Natural killer (NK) cells were
identified using flow cytometry as NK1.1+CD3− lymphocytes and were further characterized based on CD11b and CD27 expression. DN, double
negative NK cells, I = CD27+CD11b− immature NK cells, II = CD27+CD11b+ pro-inflammatory NK cells, III = CD27−CD11b+ cytotoxic NK cells; n = 5
to 11 mice per group. *P <0.05 compared to “Before CLP”.
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CXCL10 in the pathogenesis of septic shock. Seyoum et al.
reported that virulent strains of S. pneumoniae induce
high CXCL10 expression and that CXCR3-deficient mice
exhibit attenuated pulmonary inflammation and improved
outcomes during sepsis caused by Streptococcal pneumo-
nia [26]. In further studies, Martin and colleagues showed
that virulent strains of methicillin-resistant Staphylococus
aureus (MRSA) induced high concentrations CXCL10
in the lung after intrapulmonary challenge and that
CXCR3 neutralization decreases intrapulmonary inflamma-
tion [27]. The present studies show that CXCL10-deficient
mice are resistant to CLP-induced septic shock and more
directly support a cause-and-effect relationship between
CXCL10 and the pathogenesis of sepsis.
The production of CXCL10 is largely regulated by acti-
vation of type I and type II IFN receptors by IFNα/β and
IFNγ, respectively [28,29]. The transcription factor STAT-1
is an important mediator for IFN-induced gene tran-
scription and plays a central role in regulating CXCL10
expression [29-31]. Previous studies from our laboratory
show that STAT1-deficient mice are resistant to CLP-
induced septic shock [32]. STAT1 knockout mice exhib-
ited improved survival, attenuated systemic inflammation
and diminished CXCL10 production during CLP-induced
sepsis. In additional studies, decreased systemic inflam-
mation and improved survival have been demonstrated
in type 1 IFN receptor- and IFNβ-deficient mice during
fulminant CLP-induced peritonitis and endotoxin-induced
shock, respectively [33-35]. Dejager et al. reported that
blockade of type I IFN signaling was protective in models
of endotoxin and CLP-induced severe sepsis [35]. In other
studies, Lachance and colleagues showed that IFNγ-
deficient mice are resistant to septic shock caused by a
virulent strain of Streptococcus suis [36]. That finding
is consistent with previous studies that demonstrated
attenuated hyperinflammation and improved survival in
IFNγ-deficient mice in models of CLP- and endotoxin-
induced shock [37,38]. Taken together, those prior find-
ings and the results from the present study support a
role of IFNα/β, IFNγ and CXCL10 in the pathogenesis
of septic shock.
As with other mediators of hyperinflammation and
shock during systemic bacterial infections, it is likely
that CXCL10 as well as IFNα/β and IFNγ play beneficial
roles in the containment of local and less severe sys-
temic infections. Kelly-Scumpia and colleagues reportedthat type I IFN receptor-deficient mice have increased
susceptibility to lower severity CLP-induced sepsis in
which control mice showed mortality rates of less than
10% [39]. The heightened susceptibility was associated
with impaired bacterial clearance. They further reported
that the vulnerability can be reversed by treatment with
CXCL10 and concluded that CXCL10 is an important
regulator of antimicrobial function during low-severity
CLP-induced sepsis in adult mice. Reim et al. also reported
that IFN-inducible responses, including production of
CXCL10, are beneficial for facilitating bacterial clearance
mechanisms in a lower-severity model of CLP-induced
sepsis [40]. In further studies, Cuenca et al. showed that
CXCL10 is important for neutrophil and macrophage
recruitment during neonatal sepsis [41]. In those studies,
blockade of CXCL10 decreased myeloid cell recruitment
to the site of infection, decreased bacterial clearance and
increased mortality. Likewise, neonatal CXCR3KO mice
showed decreased numbers of neutrophils and macro-
phages at the site of infection and increased mortality
compared to wild-type controls. The investigators pos-
tulated that CXCL10 regulates beneficial myeloid cell
recruitment during bacterial sepsis in neonatal mice.
Interestingly, significantly decreased bacterial counts were
observed in the blood and lungs, but not peritoneal cavity,
of CXCL10 knockout mice in our study. However, differ-
ences in bacterial burden were not observed at any of the
sites tested in mice treated with anti-CXCL10. Those find-
ings indicate that CXCL10 could have a small inhibitory
effect on bacterial clearance during severe sepsis. In toto,
these combined findings indicate that CXCL10 production
can be beneficial or deleterious depending on the severity
of sepsis.
The mechanisms by which CXCL10 facilitates systemic
inflammation and physiologic dysfunction during severe
sepsis remain to be fully ascertained. CXCL10 activates
the chemokine receptor CXCR3 and is an important regu-
lator of lymphocyte trafficking in a variety of diseases char-
acterized by infection or inflammation [1,2,11]. CXCR3 is
expressed primarily by NK, NKT and T lymphocytes,
all of which have been implicated in the pathogenesis
of septic shock [1]. Previous studies from our laboratory
and from others have demonstrated that NK and CD8+ T
cells contribute to systemic inflammation and physiologic
dysfunction during sepsis or polytrauma [17,42-44]. Hu
and colleagues reported that NKT cells play a functional
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Figure 6 Lymphocyte activation during cecal ligation and puncture (CLP)-induced sepsis in wild-type and CXC chemokine 10 (CXCL10)-
deficient mice. Intraperitoneal leukocytes were harvested prior to or 6 hours after CLP. Surface CD69 expression was measured on natural killer
(NK) (NK1.1+CD3−), NKT (NK1.1+CD3+) and T (NK1.1−CD3+) lymphocytes using flow cytometry; n = 5 to 6 mice per group. *P <0.05 compared to
“Before CLP”, +P <0.05 compared to wild-type.




Figure 7 Effect of CXC chemokine 10 (CXCL10) blockade on
survival during cecal ligation and puncture (CLP)-induced sepsis.
Mice were treated with non-specific IgG or polyclonal anti-CXCL10 IgG
1 hour prior to CLP. Mice then underwent CLP and were monitored for
survival. Mice received intraperitoneal resuscitation with 1 ml of lactated
Ringer’s solution with primaxin (25 mg/kg) at the time of CLP; n = 10 to
15 mice per group, *P <0.05 compared to IgG-treated mice.
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tate systemic inflammation during lethal challenge with
lipopolysaccharide (LPS) [45,46]. Evidence indicates that
CXCR3+ NK cells migrate into the inflamed peritoneal
cavity from blood and spleen early during the course of
CLP-induced sepsis. In addition, CXCR3-mediated NK
cell trafficking parallels the development of physiologic
dysfunction and systemic inflammation during experi-
mental septic shock [11,17]. In the present study, we
observed trafficking of NK cells from spleen to periton-
eal cavity within 6 hours after CLP and extended our
previous findings by showing the migration of both the
CD27+CD11b+ pro-inflammatory and CD27−CD11b+
cytotoxic NK cell subsets. Yet, differences in NK cell
trafficking were not observed when comparing wild-
type and CXCL10-deficient mice. That finding indicates
that CXCL10 alone is not responsible for NK cell traf-
ficking during CLP-induced sepsis, which is not sur-
prising, given the redundancy of CXCR3 ligands [1].
Our previous studies show that high levels of the
CXCR3 ligands CXCL9 and CXCL10 are produced after
CLP and that a concentration gradient exists such that
concentrations of each cytokine are higher in the peri-
toneal cavity than in plasma [11]. Thus, it is likely that
CXCL9 also contributes to CXCR3-mediated NK cell
trafficking and serves as an important NK cell chemo-
attractant in the absence of CXCL10. Further studies
are required to fully define the chemokine milieu that
mediates NK cell trafficking during sepsis.
Although CXCL10-mediated NK cell trafficking does
not appear to be a crucial factor in facilitating the devel-
opment of shock in the CLP model, CXCL10-inducedNK cell activation may play a role. NK cell activation
and systemic inflammation were attenuated in CXCL10-
deficient mice as indicated by lessened expression of the
early activation marker CD69 by intraperitoneal NK cells
and decreased systemic cytokine production. This raises
the possibility that CXCL10 serves as an activating factor
for NK cells, independent of its role as a chemotactic
agent. Previous studies have shown that CXCL10 can
facilitate systemic inflammation during acute inflam-
matory syndromes [22,47]. However, further work is
needed to determine how CXCL10 facilitates the pro-
inflammatory functions of innate lymphocytes during
severe sepsis.
It appears that CXCL10 has the potential to serve as a
therapeutic target during acute septic shock. In the
present study, blockade of CXCL10, in combination with
antibiotic treatment at 6 hours after CLP was effective in
improving survival compared to mice treated with non-
specific IgG and antibiotics. Our assessment indicates
that mice show signs of sepsis at 6 hours after CLP as
indicated by the presence of hypothermia, metabolic
acidosis and bacteremia. Further work is needed to fully
define the potential application of CXCL10 blockade as
a therapeutic agent during the acute phase of septic
shock. Treatment with IgG molecules, as used in this
study, is an attractive approach to altering host immune
responses in numerous diseases with immunological or
inflammatory etiologies [48,49]. Based on our current
observations, immunoglobulin-based strategies appear
to represent an attractive strategy for blocking CXCL10
in the setting of severe sepsis. However, there are po-
tential drawbacks to immunoglobulin-based treatment
approaches, the most important of which is the persist-
ence of immunoglobulins in the circulation after systemic
administration. Long-lived blockade of CXCL10 function
could be deleterious to mounting effective downstream
anti-microbial responses in patients with sepsis as demon-
strated by the studies of Kelly-Scumpia and colleagues
[39]. An alternative approach is the use of short-acting
small molecular weight inhibitors to block CXCL10 or its
receptor, CXCR3. AMG487 is a potent and selective non-
competitive CXCR3 inhibitor that has been widely tested
in humans [50]. AMG487 undergoes hepatic metabolism
and exhibits linear pharmacokinetics during the first 7 days
of administration with a half-life of 9.7 hours [51]. Thus,
short-acting inhibitors of the CXCL10-CXCR3 axis could
serve as attractive agents to apply during the acute phase
of sepsis.
Conclusions
This report shows that CXCL10 deficiency or blockade
improves survival, decreases physiologic dysfunction
and attenuates systemic cytokine production in mice



























































Figure 8 Effect of CXC chemokine 10 (CXCL10) blockade on rectal temperature and plasma cytokine concentrations during cecal
ligation and puncture (CLP)-induced sepsis. Mice were treated with non-specific IgG (IgG, 100 ug intraperitoneal (IP)) or anti-CXCL10 IgG
(anti-CXCL10, 100 ug IP) 1 hour prior to CLP. Mice received IP resuscitation with 1 ml of lactated Ringer’s solution plus primaxin (25 mg/kg) at
the time of CLP; n = 10 mice per group, *P <0.05 compared to control, +P <0.05 compared to non-specific IgG-treated mice. αCXCL10, anti-CXCL10
IgG. Measurements were made at 24 hours after CLP. MIP-2, Macrophage inhibitory protein-2.























Figure 9 (See legend on next page.)
Herzig et al. Critical Care 2014, 18:R113 Page 14 of 18
http://ccforum.com/content/18/3/R113
(See figure on previous page.)
Figure 9 Effect of CXC chemokine 10 (CXCL10) blockade on bacterial burden during cecal ligation and puncture (CLP)-induced sepsis.
Plasma and tissue bacterial counts were measured in mice treated with or without primaxin after CLP. Mice were treated with non-specific IgG
(IgG, 100 ug intraperitoneal (IP)) or anti-CXCL10 IgG (anti-CXCL10, 100 ug IP) 1 hour prior to CLP. Mice received intraperitoneal resuscitation with 1 ml
of lactated Ringer’s solution, with or without primaxin (25 mg/kg), at the time of CLP; n = 10 mice per group, +P <0.05 compared to “- Primaxin” group.
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Figure 10 Progression of sepsis in the cecal ligation and puncture (CLP) model. Mice underwent sham or CLP procedures and rectal
temperature was measured at the indicated time points. At 6 hours after CLP blood was harvested for measurement of plasma cytokines,
acid-base balance and bacterial burden; n = 5 to 10 mice per group, *P <0.05 compared to 0 hour (no CLP) control or sham. MIP-2, Macrophage
inhibitory protein-2.
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Figure 11 CXC chemokine 10 (CXCL10) blockade improves
survival when initiated after cecal ligation and puncture (CLP)
CPS. Mice underwent CLP and were monitored for survival. Mice were
treated with anti-CXCL10 IgG (anti-CXCL10, 100 μg intravenously (IV))
or non-specific IgG (IgG, 100 μg IV) at 2 or 6 hours after CLP. Mice
received intraperitoneal resuscitation with 1 ml of lactated Ringer’s
solution and primaxin (25 mg/kg) at the time of IgG treatment; n = 20
(2 hours post-treatment) to 25 (6 hours post-treatment) mice per
group; *P <0.05 compared to mice treated with non-specific IgG.
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http://ccforum.com/content/18/3/R113blockade were evident when anti-CXCL10 IgG was ad-
ministered at 6 hours after the initiation of sepsis. Our
current findings suggest that CXCL10 may contribute
to the activation of innate lymphocyte populations, par-
ticularly NK cells, during acute septic shock. Further re-
search is needed to fully define the mechanisms by
which CXCL10 facilitates the pathogenesis of septic
shock and to define the potential of CXCL10 blockade
as a therapeutic intervention.
Key messages
 High levels of CXL10 are produced during
experimental and clinical sepsis.
 CXCL10 deficiency or blockade attenuates
systemic cytokine production, lessens physiologicdysfunction and improves survival during
experimental septic shock.
 CXCL10 contributes to the activation of NK cells
during the acute phase of sepsis but does not act
alone to facilitate NK cell trafficking.
 CXCL10 could serve as a therapeutic target during
the acute phase of sepsis.
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